{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:46:29Z","timestamp":1777355189068,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tissue and Cell"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.tice.2024.102516","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T01:59:28Z","timestamp":1722650368000},"page":"102516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Krebs von den Lungen-6 as biomarker of the new progressive fibrotic phenotype of interstitial lung disease"],"prefix":"10.1016","volume":"90","author":[{"given":"Miriana","family":"d\u2019Alessandro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Conticini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Bergantini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Antonietta","family":"Mazzei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Bellisai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Selvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Cameli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Bargagli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tice.2024.102516_bib1","article-title":"Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis","author":"A Y","year":"2006","journal-title":"Respirology"},{"issue":"2","key":"10.1016\/j.tice.2024.102516_bib2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1164\/ajrccm\/143.2.219","article-title":"Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis","volume":"143","author":"Agust\u00ed","year":"1991","journal-title":"Am. Rev. Respir. Dis."},{"issue":"7","key":"10.1016\/j.tice.2024.102516_bib3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s004310100763","article-title":"Clinical significance of the serum surfactant protein D and KL-6 levels in patients with measles complicated by interstitial pneumonia","volume":"160","author":"Arai","year":"2001","journal-title":"Eur. J. Pediatr."},{"issue":"8\u20139","key":"10.1016\/j.tice.2024.102516_bib4","first-page":"756","article-title":"Idiopathic pulmonary fibrosis:pathophysiological data","volume":"95","author":"Ayed","year":"2017","journal-title":"Tunis. Med"},{"issue":"3","key":"10.1016\/j.tice.2024.102516_bib5","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.resinv.2019.02.001","article-title":"Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib","volume":"57","author":"Bergantini","year":"2019","journal-title":"Respir. Investig."},{"key":"10.1016\/j.tice.2024.102516_bib6","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8565423","article-title":"Prognostic biomarkers of sarcoidosis: a comparative study of serum chitotriosidase, ACE, lysozyme, and KL-6","volume":"2019","author":"Bergantini","year":"2019","journal-title":"Dis. Markers"},{"issue":"1","key":"10.1016\/j.tice.2024.102516_bib7","first-page":"27","article-title":"Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement","volume":"28","author":"Bonella","year":"2011","journal-title":"Sarcoid. Vasc. Diffus. Lung Dis."},{"key":"10.1016\/j.tice.2024.102516_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12931-023-02588-y","article-title":"Hospitalisation patterns in interstitial lung diseases: data from the EXCITING-ILD registry","volume":"25","author":"Buschulte","year":"2024","journal-title":"Respir. Res."},{"key":"10.1016\/j.tice.2024.102516_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.973918","article-title":"Krebs von den Lungen-6 glycoprotein circulating levels are not useful as prognostic marker in COVID-19 pneumonia: a large prospective cohort study","author":"Castellv\u00ed","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.tice.2024.102516_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.799912","article-title":"The burden of progressive-fibrosing interstitial lung diseases","volume":"9","author":"Cottin","year":"2022","journal-title":"Front. Med."},{"issue":"11","key":"10.1016\/j.tice.2024.102516_bib11","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1164\/rccm.201710-1981ST","article-title":"Recommendations for a standardized pulmonary function report. An official American thoracic society technical statement","volume":"196","author":"Culver","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.tice.2024.102516_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13543","article-title":"Prognostic role of KL-6 in SSc-ILD patients with pleuroparenchymal fibroelastosis","author":"d\u2019Alessandro","year":"2021","journal-title":"Eur. J. Clin. Investig."},{"issue":"12","key":"10.1016\/j.tice.2024.102516_bib13","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.3390\/life11121401","article-title":"Extracellular vesicles in pulmonary fibrosis models and biological fluids of interstitial lung disease patients: a scoping review","volume":"11","author":"d\u2019Alessandro","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.tice.2024.102516_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13242","article-title":"Serum KL-6 levels in pulmonary Langerhans\u2019 cell histiocytosis","author":"d\u2019Alessandro","year":"2020","journal-title":"Eur. J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.tice.2024.102516_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040689","article-title":"Serum concentrations of KL-6 in patients with IPF and lung cancer and serial measurements of KL-6 in IPF patients treated with antifibrotic therapy","volume":"13","author":"d\u2019Alessandro","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.tice.2024.102516_bib16","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.3390\/ijerph19042176","article-title":"Krebs von den Lungen-6 as disease severity marker for COVID-19 patients: analytical verification and quality assessment of the Tosoh AIA-360 compared to lumipulse G600II","volume":"19","author":"d\u2019Alessandro","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.tice.2024.102516_bib17","article-title":"Efficacy of baricitinib in treating rheumatoid arthritis: modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting","volume":"86","author":"d\u2019Alessandro","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.tice.2024.102516_bib18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.23736\/S0026-4806.21.07322-5","article-title":"Prognostic role of KL-6 in lymphangioleiomyomatosis patients","volume":"113","author":"D\u2019Alessandro","year":"2022","journal-title":"Minerva Med."},{"issue":"11","key":"10.1016\/j.tice.2024.102516_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.tice.2024.102516_bib20","doi-asserted-by":"crossref","first-page":"10196","DOI":"10.3390\/ijms241210196","article-title":"Acute exacerbations of interstitial lung diseases: focus on biomarkers","volume":"24","author":"Drakopanagiotakis","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"18","key":"10.1016\/j.tice.2024.102516_bib21","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.tice.2024.102516_bib22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/cc11224","article-title":"Repair after acute lung injury: molecular mechanisms and therapeutic opportunities","volume":"16","author":"Gonz\u00e1lez-L\u00f3pez","year":"2012","journal-title":"Crit. Care"},{"issue":"2","key":"10.1016\/j.tice.2024.102516_bib23","first-page":"149","article-title":"ATS\/ERS\/WASOG statement on sarcoidosis. American Thoracic Society\/European Respiratory Society\/World Association of Sarcoidosis and other Granulomatous Disorders","volume":"16","author":"Hunninghake","year":"1999","journal-title":"Sarcoid. Vasc. Diffus. Lung Dis."},{"issue":"2","key":"10.1016\/j.tice.2024.102516_bib24","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.chest.2020.03.037","article-title":"Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases with a progressive phenotype","volume":"158","author":"Inoue","year":"2020","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.tice.2024.102516_bib25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.resinv.2012.02.001","article-title":"Utility of KL-6\/MUC1 in the clinical management of interstitial lung diseases","volume":"50","author":"Ishikawa","year":"2012","journal-title":"Respir. Investig."},{"issue":"6","key":"10.1016\/j.tice.2024.102516_bib26","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1378\/chest.124.6.2119","article-title":"Study of Clara cell 16, KL-6, and surfactant protein-D in serum as disease markers in pulmonary sarcoidosis","volume":"124","author":"Janssen","year":"2003","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.tice.2024.102516_bib27","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.21037\/jtd.2018.07.76","article-title":"Sequential changes of serum KL-6 predict the progression of interstitial lung disease","volume":"10","author":"Jiang","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.tice.2024.102516_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104766","article-title":"Precision medicine advances in idiopathic pulmonary fibrosis","volume":"95","author":"Karampitsakos","year":"2023","journal-title":"eBioMedicine"},{"issue":"4","key":"10.1016\/j.tice.2024.102516_bib29","doi-asserted-by":"crossref","first-page":"a022293","DOI":"10.1101\/cshperspect.a022293","article-title":"TGF-\u03b21 signaling and tissue fibrosis","volume":"10","author":"Kim","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"6 Suppl 86","key":"10.1016\/j.tice.2024.102516_bib30","article-title":"Follow-up of serum KL-6 lung fibrosis biomarker levels in 173 patients with systemic sclerosis","volume":"32","author":"Kum\u00e1novics","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.tice.2024.102516_bib31","article-title":"Research progress in the molecular mechanisms, therapeutic targets, and drug development of idiopathic pulmonary fibrosis","author":"Ma","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"14","key":"10.1016\/j.tice.2024.102516_bib32","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1007\/s00018-021-03874-y","article-title":"Idiopathic pulmonary fibrosis and systemic sclerosis: pathogenic mechanisms and therapeutic interventions","volume":"78","author":"Mattoo","year":"2021","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.tice.2024.102516_bib33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.virol.2021.11.006","article-title":"Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: a systematic review and meta-analyses","volume":"566","author":"Naderi","year":"2022","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.tice.2024.102516_bib34","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1164\/ajrccm.165.3.2107134","article-title":"Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases","volume":"165","author":"Ohnishi","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.tice.2024.102516_bib35","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s00795-007-0382-7","article-title":"Immunohistochemical and immunoelectron microscopic studies of the localization of KL-6 and epithelial membrane antigen (EMA) in presumably normal pulmonary tissue and in interstitial pneumonia","volume":"40","author":"Ohtsuki","year":"2007","journal-title":"Med. Mol. Morphol."},{"issue":"12","key":"10.1016\/j.tice.2024.102516_bib36","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.rmed.2015.10.005","article-title":"The usefulness of KL-6 and SP-D for the diagnosis and management of chronic hypersensitivity pneumonitis","volume":"109","author":"Okamoto","year":"2015","journal-title":"Respir. Med."},{"issue":"5","key":"10.1016\/j.tice.2024.102516_bib37","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"9","key":"10.1016\/j.tice.2024.102516_bib38","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.tice.2024.102516_bib39","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1164\/rccm.202005-2032ST","article-title":"Diagnosis of hypersensitivity pneumonitis in adults. An official ATS\/JRS\/ALAT clinical practice guideline","volume":"202","author":"Raghu","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"8","key":"10.1016\/j.tice.2024.102516_bib40","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3899\/jrheum.170518","article-title":"KL-6 But Not CCL-18 is a predictor of early progression in systemic sclerosis-related interstitial lung disease","volume":"45","author":"Salazar","year":"2018","journal-title":"J. Rheumatol."},{"issue":"6","key":"10.1016\/j.tice.2024.102516_bib41","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.tice.2024.102516_bib42","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/resp.13988","article-title":"Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression","volume":"26","author":"Stock","year":"2021","journal-title":"Respirology"},{"key":"10.1016\/j.tice.2024.102516_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107360","article-title":"Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma","volume":"185","author":"Stockhammer","year":"2023","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.tice.2024.102516_bib44","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12890-019-0937-0","article-title":"Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases","volume":"19","author":"Torrisi","year":"2019","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.tice.2024.102516_bib45","article-title":"Prognostic predictive characteristics in patients with fibrosing interstitial lung disease: a retrospective cohort study","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.tice.2024.102516_bib46","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1165\/rcmb.2021-0557TR","article-title":"Insights into the pathogenesis of pulmonary fibrosis from genetic diseases","volume":"67","author":"Wang","year":"2022","journal-title":"Am J Respir Cell Mol Biol."},{"issue":"1","key":"10.1016\/j.tice.2024.102516_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e23543","article-title":"Predictive biomarkers of disease progression in idiopathic pulmonary fibrosis","volume":"10","author":"Zhu","year":"2024","journal-title":"Heliyon"}],"container-title":["Tissue and Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816624002179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816624002179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T04:56:02Z","timestamp":1725080162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040816624002179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":47,"alternative-id":["S0040816624002179"],"URL":"https:\/\/doi.org\/10.1016\/j.tice.2024.102516","relation":{},"ISSN":["0040-8166"],"issn-type":[{"value":"0040-8166","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Krebs von den Lungen-6 as biomarker of the new progressive fibrotic phenotype of interstitial lung disease","name":"articletitle","label":"Article Title"},{"value":"Tissue and Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tice.2024.102516","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102516"}}